Memantine is an oral neurology medication available in a 10 mg pill formulation. It is classified as an N-methyl-D-aspartate (NMDA) receptor antagonist and is prescribed for the management of moderate to severe Alzheimer’s disease. In Hong Kong, memantine is a prescription-only product and is regulated by the Hong Kong Department of Health. The drug is marketed by several manufacturers worldwide under various brand names, but the active ingredient is identical across products.
If you are unfamiliar with NMDA receptor function, think of it as a “gatekeeper” that, when over-activated, can harm neurons. Memantine gently keeps that gate from staying open too long.
These effects are frequently reported, especially during the first weeks of therapy, and often lessen as the body adjusts.
If any of these occur, seek medical attention promptly.
This article provides educational information about memantine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, memantine is often prescribed alongside cholinesterase inhibitors such as donepezil. This combination can target different aspects of the disease, but the prescribing clinician should review potential interactions and adjust doses as needed.
Dizziness is a common early side effect. Try taking the medication with food and rise slowly from sitting or lying positions. If the symptom persists or is severe, contact your healthcare provider for possible dose adjustment.
Both contain the same active ingredient, memantine, and must meet identical quality standards set by regulatory authorities. Inactive ingredients may differ slightly, which can affect tolerability for some individuals.
Clinical observations suggest that measurable improvements or stabilization of symptoms may become apparent after 4-6 weeks of regular use, though individual responses vary.
Because memantine is cleared unchanged by the kidneys, reduced renal function can increase drug levels. Patients with severe renal impairment usually require a lower maintenance dose and closer monitoring.
Seizure risk is low, but rare cases have been reported. If you have a seizure disorder, discuss the benefits and risks with your prescriber before starting therapy.
Most dietary supplements do not interact directly with memantine. However, herbal products that affect kidney function (e.g., high-dose lithium) could theoretically alter memantine clearance; always inform your clinician of any supplements you take.
Yes, but keep the medication in its original labeled container, carry a copy of your prescription, and be aware of any import restrictions in the destination country. In Hong Kong, the Drug Office permits personal import of prescribed quantities for personal use.
Most 10 mg tablets are round, white to off-white, and may have a film coating. Specific imprint codes vary by manufacturer; check the packaging for the exact identifier.
Memantine works through NMDA antagonism, while rivastigmine is a cholinesterase inhibitor. They act on different neural pathways, and clinicians may choose one, the other, or a combination based on patient needs and tolerability.
